Alison Bauerlein
Known title: Chief Operating OfficerCIK: 0001596080
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Medical device growth debate touches Inogen sector. A recent Yahoo article examined whether ResMed or Stryker offers a better path to capture medical device growth. Inogen operates in the same medical device market, so the analysis is relevant to how the sector is being evaluated. The discussion may influence how market participants view companies that provide portable oxygen solutions.
Transaction History
| SGHT | ▼ Sell | Open Market | 25,260 | $224K | 10/2/2026 | View on chart |
| SGHT | ▼ Sell | Open Market | 24,184 | $130K | 7/2/2026 | View on chart |
| SGHT | ▼ Sell | Open Market | 12,728 | $65K | 5/18/2026 | View on chart |
| SGHT | ▼ Sell | Open Market | 25,874 | $90K | 4/2/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 127,512 | $0 | 2/3/2026 | View on chart |
| SGHT | ▼ Sell | Open Market | 9,647 | $72K | 1/6/2026 | View on chart |
| SGHT | ▼ Sell | Open Market | 10,896 | $85K | 1/5/2026 | View on chart |
| SGHT | ▲ Buy | Grant | 23,006 | $0 | 11/11/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 19,948 | $66K | 10/2/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 19,260 | $79K | 7/2/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 13,066 | $45K | 5/19/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 19,397 | $45K | 4/2/2025 | View on chart |
| SGHT | ▲ Buy | Grant | 286,738 | $0 | 3/11/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 10,102 | $36K | 1/3/2025 | View on chart |
| SGHT | ▼ Sell | Open Market | 10,130 | $62K | 10/1/2024 | View on chart |
| SGHT | ▼ Sell | Open Market | 10,497 | $65K | 7/2/2024 | View on chart |
| SGHT | ▼ Sell | Open Market | 13,066 | $71K | 5/17/2024 | View on chart |
| SGHT | ▼ Sell | Open Market | 10,123 | $51K | 4/3/2024 | View on chart |
| SGHT | ▲ Buy | Grant | 315,421 | $0 | 2/14/2024 | View on chart |
| SGHT | ▲ Buy | Grant | 103,000 | $0 | 5/9/2023 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 490 | $15K | 12/1/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 546 | $0 | 12/1/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 253 | $0 | 9/1/2021 | View on chart |
| INGN | ▲ Buy | Option Exercise | 546 | $0 | 9/1/2021 | View on chart |
| INGN | ▼ Sell | Tax Withholding | 616 | $37K | 9/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Sight Sciences to Show OMNI Ultra System at 2026 AOO Meeting
Sight Sciences plans to debut its new OMNI Ultra Surgical System at the upcoming American Academy of Ophthalmology Annual Meeting. This event highlights the company's continued focus on advancing ab interno canaloplasty technology. The stock is currently trading near its 52-week high, reflecting strong recent momentum.
Sight Sciences to Show OMNI Ultra System at 2026 AOO Meeting. Sight Sciences plans to debut its new OMNI Ultra Surgical System at the upcoming American Academy of Ophthalmology Annual Meeting. This event highlights the company's continued focus on advancing ab interno canaloplasty technology. The stock is currently trading near its 52-week high, reflecting strong recent momentum.